Pfizer (PFE)
(Delayed Data from NYSE)
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Can Allergan (AGN) Keep the Earnings Streak Alive in Q1?
by Zacks Equity Research
While Allergan's (AGN) Q1 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products is expected to hurt sales.
The Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and Pfizer
Lilly (LLY) Tops on Q1 Earnings, Raises '18 View, Stock Up
by Zacks Equity Research
Eli Lilly (LLY) beats estimates for both earnings and sales in Q1 and raises guidance for 2018. Shares rise in pre-market trading.
Is a Beat in Store for Alexion (ALXN) This Earnings Season?
by Zacks Equity Research
Impressive sales of Alexion's blockbuster drug, Soliris might lead the company toward an earnings beat in Q1.
Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy
by Sweta Killa
Let's dig into the earnings picture of the companies that would drive the performance of the popular health care ETFs in the coming days.
Will Midterms Throw Markets Helter-Skelter? 5 Top Picks
by Tirthankar Chakraborty
In the last 11 midterm election years since 1974, the S&P 500 managed to eke out gains in April, but, mostly traded flat through September only to rally once political uncertainty waned.
Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?
by Zacks Equity Research
Bristol-Myers (BMY) is scheduled to report Q1 earnings on Apr 26.
NYSE to Soon Greet The Fearless Girl Statue
by Sweta Killa
The Fearless Girl statue, a global symbol of female business prowess, is moving in front of the New York Stock Exchange by the end of this year.
What's in the Cards for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might aid the company's results in Q1.
Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Lilly's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
Healthcare ETFs in Focus After Johnson & Johnson Q1 Earnings
by Zacks Equity Research
Johnson & Johnson reports Q1 results with both revenues and EPS beating estimates.
3 Dividend ETFs With High Inflows in April
by Zacks Equity Research
Consider these three dividend ETFs to fend off growing market uncertainty.
5 Drug Stocks Poised to Surpass on Earnings This Quarter
by Zacks Equity Research
The outlook for the upcoming first-quarter results looks bright.
Bristol-Myers (BMY) Down as Merck NSCLC Study Fares Better
by Zacks Equity Research
Bristol-Myers (BMY) stock declined as the company reported encouraging results from its NSCLC study but competitor Merck scored better in the same regard.
What's in Store for Novartis (NVS) This Earnings Season?
by Zacks Equity Research
We expect investors to focus on the performance of newly launched drugs when Novartis (NVS) reports its first-quarter results.
J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2018. It maintains the previously issued earnings guidance for 2018 while increasing the sales range.
Shire Sells Oncology Unit Ahead of Takeda's Potential Offer
by Zacks Equity Research
Shire (SHPG) sells its oncology segment to France-based Servier for $2.4 billion. Takeda remains on track to make a potential offer for Shire.
Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III
by Zacks Equity Research
Novartis (PFE) to buy AveXis for $8.7 billion. Merck's (MRK) Keytruda succeeds in another key lung cancer study. AbbVie's (ABBV) upadacitinib met endpoints in the 4th phase III study from its SELECT program.
Pfizer Starts Phase Ib for Duchenne Muscular Dystrophy Drug
by Zacks Equity Research
Pfizer (PFE) commences dosing in a phase Ib study, evaluating its gene therapy candidate, PF-06939926, for treating five to 12-yearold boys with duchenne muscular dystrophy.
Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus
by Zacks Equity Research
With the announcement of Novartis (NVS) acquiring AveXis, a clinical stage gene therapy company, several companies have started to develop the therapy with many of them having promising candidates in their pipelines.
Glaxo to Sell Rare Disease Gene Therapies to Private Biotech
by Zacks Equity Research
Glaxo (GSK) will divest its rare disease gene therapy drugs to private biotech Orchard Therapeutics in exchange for a 19.9% stake in the company as well as a seat on its board.
Top ETF Picks for Your IRA
by Neena Mishra
Low-cost, diversified ETFs are excellent investment vehicles to build retirement wealth.
Pfizer's Kidney Cancer Drug Misses Endpoint in Phase III
by Zacks Equity Research
Pfizer's (PFE) kidney cancer drug Inlyta (axitinib) fails to demonstrate a clear improvement in the primary endpoint of extending disease-free survival (DFS) in a late-stage study.
AbbVie's RA Candidate Meets Primary Endpoints in Phase III
by Zacks Equity Research
AbbVie's (ABBV) rheumatoid arthritis candidate, upadacitinib, meets both primary and secondary endpoints in the fourth phase III SELECT study for the given indication.
Agios Pharmaceuticals Shares Rise on Buyout Speculation
by Zacks Equity Research
Agios (AGIO) share price shoots up on probable acquisition by other biggies in the biotech industry. This optimism follows the news of Novartis striking a deal to buy gene therapy company, AveXis.